Agensys, Inc. and Seattle Genetics, Inc. (SGEN) Announce Interim Phase I Data from ASG-5ME Clinical Trial for Prostate Cancer  
6/4/2012 10:40:53 AM

SANTA MONICA, Calif. & BOTHELL, Wash.--(BUSINESS WIRE)--Agensys, Inc., an affiliate of Tokyo-based Astellas Pharma Inc., and Seattle Genetics, Inc. (Nasdaq: SGEN) today announced interim data from a phase I clinical trial evaluating ASG-5ME for the treatment of castration-resistant prostate cancer (CRPC). ASG-5ME is an antibody-drug conjugate (ADC) targeting the SLC44A4 antigen that is being co-developed by both companies for the treatment of solid tumors. The data are being presented at the American Society of Clinical Oncology (ASCO) annual meeting being held June 1-5, 2012 in Chicago, IL.